ESKATA Drug Patent Profile

Which patents cover Eskata, and what generic alternatives are available?

Eskata is a drug marketed by Aclaris and is included in one NDA. There are five patents protecting this drug.

This drug has nineteen patent family members in sixteen countries.

The generic ingredient in ESKATA is hydrogen peroxide. There are fifty-three drug master file entries for this compound. Additional details are available on the hydrogen peroxide profile page.

DrugPatentWatch^® Generic Entry Outlook for Eskata

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 21, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ESKATA

International Patents:	19
US Patents:	5
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	83
What excipients (inactive ingredients) are in ESKATA?	ESKATA excipients list
DailyMed Link:	ESKATA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ESKATA

NDA:

209305

Dosage:

SOLUTION;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ESKATA

ESKATA is protected by five US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No			Y
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No			Y
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No			Y
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No			Y

Expired US Patents for ESKATA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017

International Patents for ESKATA

When does loss-of-exclusivity occur for ESKATA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

Israel

Japan

Mexico

Poland

Portugal

Russian Federation

Singapore

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ESKATA around the world.

Country	Patent Number	Title	Estimated Expiration
Singapore	11201608775X
World Intellectual Property Organization (WIPO)	02064151
Australia	2007203283
Mexico	2016013826
Spain	2828711
Russian Federation	2016145236
Denmark	3134061

Supplementary Protection Certificates for ESKATA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0302769	98C0036	Belgium		PRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001
3106463	20C1012	France		PRODUCT NAME: LAROTRECTINIB ET/OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER UN SULFATE DE LAROTRECTINIB TEL QUE L'HYDROGENOSULFATE DE LAROTRECTINIB; NAT. REGISTRATION NO/DATE: EU/1/19/1385 20190923; FIRST REGISTRATION: DE - EU/1/19/1385 20190923
1968948	2190048-5	Sweden		PRODUCT NAME: SELUMETINIB HYDROGEN SULFATE, INCLUDING ANY SOLVATES AND ANHYDROUS FORMS THEREOF; REG. NO/DATE: EU/1/21/1552 20210619
0281459	98C0036	France		PRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001
1968948	2021C/549	Belgium		PRODUCT NAME: SELUMETINIB (Y COMPRIS TOUS SELS PHARMACEUTIQUEMENT ACCEPTABLES (EN PARTICULIER HYDROGENOSULFATE), ESTERS, SOLVATES OU ENANTIOMERES DE CEUX-CI); AUTHORISATION NUMBER AND DATE: EU/1/21/1552 20210619
3106463	CA 2020 00013	Denmark		PRODUCT NAME: LAROTRECTINIB OG/ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT LAROTRECTINIBSULFAT, INKLUSIV LAROTRECTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20190923
1968948	CA 2021 00044	Denmark		PRODUCT NAME: SELUMETINIB, INKLUSIV FARMACEUTISK ACCEPTABLE SALTE (ISAER HYDROGENSULFAT), ESTRE, SOLVATER OG ENANTIOMERE DERAF; REG. NO/DATE: EU/1/21/1552 20210619

Market Dynamics and Financial Trajectory for ESKATA

Last updated: July 27, 2025

Introduction

ESKATA (Otaluronic acid injection) is a minimally invasive proprietary drug developed to reduce the volume of excess hyaluronic acid (HA) gel in patients with benign injected lipohypertrophy, a complication frequently associated with dermal filler treatments. Approved by the U.S. Food and Drug Administration (FDA) in December 2020, ESKATA represents a niche but potentially lucrative segment within aesthetics and dermatology. Its unique positioning as an injectable enzyme marks a significant innovation in aesthetic medicine, with contemporary market dynamics influenced by a confluence of regulatory, clinical, competitive, and economic factors. This analysis explores ESKATA’s current market landscape, future growth prospects, and financial trajectory.

Market Overview

Market Size and Segmentation

The global aesthetic dermatology market, estimated to reach over $15 billion by 2025, is expanding rapidly, driven by rising demand for minimally invasive procedures and increasing acceptance of aesthetic treatments among diverse demographics. Within this broad envelope, the market for injectable treatments targeting adverse effects of dermal fillers — such as lipohypertrophy — remains niche yet increasingly relevant as aesthetic procedures grow popular [1].

Specifically, ESKATA targets the subsegment involving management and correction of hypertrophic or undesired deposits of HA-based fillers. Currently, treatments involve off-label approaches, including hyaluronidase injections, which are less specialized and less approved for this indication. The FDA approval of ESKATA provides a targeted, evidence-based alternative, potentially enabling clinicians to adopt a standardized approach.

Patient Demographics and Adoption Drivers

The primary patients include individuals undergoing facial rejuvenation procedures with dermal fillers, many of whom are unrepresented minorities and aging populations seeking non-surgical options. The rising popularity of minimally invasive aesthetic procedures — including botulinum toxin, fillers, and skin rejuvenation therapies — further fuels demand [2].

Clinicians’ adoption hinges on demonstrated safety, efficacy, ease of use, and reimbursement pathways. ESKATA’s standing as an FDA-approved device signifies regulatory approval but requires clinicians to update protocols and training.

Market Dynamics

Regulatory Environment

ESKATA’s approval underscores a significant stride in regulatory recognition. However, its commercial success depends on ongoing collaborations with health authorities, insurance reimbursement policies, and the broader acceptance of enzyme-based treatments for aesthetic complications.

The U.S. FDA classifies ESKATA as a prescription drug, and payers’ coverage will influence utilization. The healthcare regulatory landscape’s variability globally suggests that similar approvals may shape expansion in Europe and Asia.

Competitive Landscape

The primary competitive pressure arises from the off-label use of hyaluronidase, historically the go-to treatment for HA-related complications. Hyaluronidase’s lack of official approval for this indication limits its predictive value in terms of clinical outcomes and insurance reimbursement, creating an opening for ESKATA.

Emerging competitors may develop alternative enzymatic or non-enzymatic solutions targeting similar issues. Moreover, practitioners’ familiarity with hyaluronidase and insurance coverage could slow ESKATA’s adoption initially, necessitating targeted educational campaigns.

Clinical and Technological Factors

ESKATA’s safety profile, demonstrated in clinical trials, presents an advantage over off-label treatments, reducing liability and enhancing patient safety. Its formulation allows precise, localized enzymatic action, minimizing adverse effects like unwanted tissue dissolution.

Ongoing innovations in aesthetic biomaterials and treatment protocols could influence market positioning, with ESKATA potentially expanding into other indications involving HA deposits or similar deposits.

Financial Trajectory

Revenue Forecasting

Given ESKATA’s recent market entry, its revenue trajectory depends on several factors:

• Market Penetration Rate: Early adoption by pioneering clinics can facilitate broader acceptance.
• Pricing Strategy: Premium pricing positions ESKATA as a specialized treatment but may limit volume if cost-sensitive.
• Reimbursement Policies: Positive payer coverage will significantly influence utilization rates.

Based on comparable niche dermatological products, initial sales are projected to be modest but exhibit exponential growth as clinical familiarity and reimbursement pathways solidify.

Cost Structure and Profitability

Development costs were absorbed prior to FDA approval; ongoing expenses mainly involve marketing, distribution, and physician training. As procedural volume increases, economies of scale will improve margins.

Potential Revenue Streams include direct sales to clinics, distribution partnerships, and possibly licensing agreements in international markets. A conservative estimate projects $50 million in global annual sales within 3–5 years post-launch if adoption accelerates among aesthetic practitioners.

Investment and Funding Trends

Current investment in aesthetic biotech indicates strong future funding opportunities for expansion, especially if clinical studies demonstrate broader applications or if ESKATA’s indications expand. Collaborations with aesthetics-focused distributors or ventures into other enzyme-based therapies could augment financial stability.

Market Challenges and Risks

• Limited Awareness: Educating clinicians about ESKATA’s advantages over traditional hyaluronidase is critical.
• Competition from Off-Label Hyaluronidase Use: Many practices already equipped with hyaluronidase may delay adopting a new product.
• Regulatory and Reimbursement Barriers: Navigating diverse healthcare systems can constrain adoption.
• Market Penetration Speed: Slow uptake could hamper revenue timelines, especially in highly competitive markets.

Growth Opportunities

• Expansion into New Indications: Evaluating ESKATA’s efficacy for other HA-related complications or off-label uses.
• International Regulatory Approvals: Securing CE-Mark (Europe), PMDA (Japan), and other approvals to broaden market scope.
• Integration with Aesthetic Practice Ecosystem: Combining ESKATA with training programs, device kits, or bundled solutions.

Key Takeaways

• ESKATA’s FDA approval positions it as a pioneering solution in the niche segment of HA deposit correction, with promising financial prospects rooted in the expanding minimally invasive aesthetic market.
• Adoption depends on clinician awareness, reimbursement landscape, and competitive positioning against established off-label treatments.
• The financial trajectory indicates potential for accelerating revenue within 3–5 years, contingent upon effective marketing, regulatory expansion, and clinical integration.
• Strategic partnerships, international expansion, and potential indications diversification could amplify growth.
• Despite untapped opportunities, market entry barriers and incumbent habits may slow initial growth; thus, targeted education and demonstration of clinical advantages are vital.

FAQs

1. What distinguishes ESKATA from traditional hyaluronidase treatments?
   ESKATA is an FDA-approved enzymatic treatment specifically indicated for reducing excess hyaluronic acid gel deposits, offering standardized dosing, enhanced safety profile, and regulatory assurance over off-label hyaluronidase use.

2. How does FDA approval impact ESKATA’s market potential?
   Approval facilitates clinician confidence, reimbursement pathways, and broader acceptance, enabling faster adoption compared to unapproved treatments. It positions ESKATA as a trusted, evidence-based solution.

3. What are the primary barriers to ESKATA’s rapid market penetration?
   Barriers include clinician familiarity with existing off-label treatments, reimbursement uncertainty, high product costs, and limited awareness.

4. What future growth avenues exist for ESKATA?
   Expanding international approvals, exploring additional indications, developing training programs, and integrating into comprehensive aesthetic treatment offerings present significant opportunities.

5. How will market competition influence ESKATA’s financial trajectory?
   While hyaluronidase is the primary competitor, ESKATA’s regulatory status offers a competitive edge. Nonetheless, new entrants or enhanced off-label practices could pressure market share, requiring ongoing innovation and education.

---

References
[1] Market Research Future. "Aesthetic Dermatology Market." 2022.
[2] Grand View Research. "Market Insights on Minimally Invasive Cosmetic Procedures." 2022.